Research published in Scientific Reports journal has suggested that botulinum toxin (BoNT-A) could be used as an effective treatment for patients with depression.
Xeomin® has received cosmetic approval from the US Food and Drug Administration (FDA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.
A clinical study conducted by global pharmaceutical company Allergan suggests that higher doses of Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe glabella lines produces greater duration of treatment effect.
The results of two studies conducted by pharmaceutical company Galderma (UK) Limited have demonstrated high patient satisfaction for the use of Azzalure (AbobotulinumtoxinA), its botulinum toxin type A product, in the glabellar complex.
Polydioxanone (PDO) thread range, Elionce, has been released in the UK.
New technology will be in place from January 31 to monitor advertisements on social media relating to the promotion of prescription-only medicines (POMs) such as botulinum toxin.
Healthcare Improvement Scotland (HIS) has confirmed in a Stakeholder meeting earlier this week that aesthetic nurses who own HIS-registered clinics can now legally stock prescription only medications (POMs) such as botulinum toxin and hyaluronidase on premises.
Aesthetic product manufacturer BioScience GmbH has received the European Commission approved CE mark extension for all its hyaluronic acid based dermal filler ranges HYAcorp, Genefill and HYAprof.
Global pharmaceutical company Allergan has announced key future growth drivers for its medical aesthetics portfolio at its first ever Medical Aesthetics Analyst Day this month.
Aesthetic distributor Merz Aesthetics will introduced a new cellulite treatment to the UK and Ireland in early 2017.